Trial Profile

A Phase I study of Radioligand Therapy 212Pb-GRPR in Patients With Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs 212Pb-gastrin-releasing-peptide-receptor-targeted-alpha-therapy-Orano-Med (Primary)
Indications Breast cancer; Lung cancer; Prostate cancer; Solid tumours
Focus Adverse reactions
Sponsors Orano Med

Most Recent Events

09 Jan 2023 New trial record
04 Jan 2023 According to Ornao Med media release, the first patient has been dosed in this study

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com